Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Todos Medical Ltd (OP: TOMDF )

0.0006 +0.0001 (+20.00%)
Streaming Delayed Price Updated: 1:42 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Todos Medical Ltd

< Previous 1 2 Next >
Todos Medical to Present at January 5, 2022 Emerging Growth Conference
New York, NY, and Tel Aviv, ISRAEL – January 3, 2021 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced... 
Via Benzinga
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The... 
Via Benzinga
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer's Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
CEO Gerald Commissiong is also scheduled to appear on BNC at 1:50PM EST to discuss the authorization of Pfizer’s COVID antiviral drug & Tollovir™ Phase 2 for... 
Via Benzinga
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
Provista completed validation for fingerprick At-Home sample collection of blood for the cPass neutralizing antibody test New York, NY, and Tel Aviv, ISRAEL... 
Via Benzinga
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Company retains iiiNTENT SAAS artificial intelligence marketing service for Tollovid® and Tollovid Daily™ 3CL protease inhibitor dietary supplement products... 
Via Benzinga
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Company retains iiiNTENT SAAS artificial intelligence marketing service for Tollovid® and Tollovid Daily™ 3CL protease inhibitor dietary supplement products New York,... 
Via Benzinga
Todos Medical Announces "Test & Tollovid®" Holiday Package for Atlanta Area at Provista Diagnostics
New York, NY, and Tel Aviv, ISRAEL – December 17, 2021 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today... 
Via Benzinga
Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19
Webinar to be held on December 22nd @ 12pm EST NLC Pharma and Todos agree to extend closing date for formation of 3CL Sciences to December 31, 2021 while the companies... 
Via Benzinga
Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
New York, NY, Alpharetta, GA and Tel Aviv, ISRAEL – December 13, 2021 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company... 
Via Benzinga
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
New York, NY, and Tel Aviv, ISRAEL – December 10, 2021 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today... 
Via Benzinga
Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
Combined testing from two contracts averages 1000 PCR samples per day Testing potential for the two contracts could ramp up to 5000 PCR samples per day New York, NY, Alpharetta... 
Via Benzinga
Exposures COVID-19
Todos Medical to Present at Upcoming Emerging Growth Conference
New York, NY, and Tel Aviv, ISRAEL – December 6, 2021 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today... 
Via Benzinga
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Dr. Jules Mitchel now leading preparation for data lock and statistical analysis Business update call Today at 4:30PM EST New York, NY, and Tel Aviv, ISRAEL – December 2,... 
Via Benzinga
Exposures COVID-19
Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST
New York, NY, and Tel Aviv, ISRAEL – December 1, 2021 - Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related... 
Via Benzinga
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Provista to also utilize e Osang’s High-Capacity Reflex Variant PCR Detection Kit that has been confirmed to identify the Omicron variant New York, NY, and Tel Aviv, ISRAEL... 
Via Benzinga
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
Company to form majority owned subsidiary, 3CL Sciences, an entity focused on the development of variant-agnostic COVID-19 antivirals such as Tollovir that utilize the 3CL... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily™ from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
T-Cell Protect is also evaluating expected demand for maximum strength Tollovid® New York, NY, and Tel Aviv, ISRAEL – November 22, 2021 - Todos Medical, Ltd. (OTCQB:... 
Via Benzinga
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir® Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Enrollment now paused in the randomized, double blind, placebo controlled clinical trial in severe and critical hospitalized COVID-19 patients to complete interim analysis Data... 
Via Benzinga
Exposures COVID-19
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
The agreement calls for a minimum of 500,000 bottles in sales over 18 months T-Cell Protect to invest 1 million euros in Todos to support development of Tollovir, the Company... 
Via Benzinga
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
Reauthorization of EUA expands beyond initial qualitative detection claim CEO to appear on Cheddar News at 6:10pm tonight, November 17th, 2021 New York, NY, and Tel Aviv, ISRAEL... 
Via Benzinga
Todos Medical's Provista Laboratory to Boost Top Line through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
New York, NY, and Tel Aviv, ISRAEL – November 16, 2021 - Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related... 
Via Benzinga
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Exposures COVID-19
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
Photo by Danilo Alvesd on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral... 
Via Talk Markets
Molnupiravir? Not So Fast. What About Tollovir? — Here's Why You Should Know What That Means
Photo by Martin Sanchez on Unsplash Merck (NYSE: MRK) announced last Friday impressive results from its COVID-19 antiviral, molnupiravir. As vaccines are requiring a third booster... 
Via Benzinga
Exposures COVID-19
These OTCQX & OTCQB Securities Had the Most Trading Activity in August
Photo by Javier Allegue Barros on Unsplash August saw a slight increase in trading volume on the OTC Markets with activity showing signs of direction coming out of the summer... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.